Cost-effectiveness plane in the base case analysis.
- Merlijn W. J. van Leent (779629)
- Jelena Stevanović (610519)
- Frank G. Jansman (779630)
- Maarten J. Beinema (779631)
- Jacobus R. B. J. Brouwers (779632)
- Maarten J. Postma (239601)
Publication date
August 2015
DOIAbstract
<p>The graph shows the results of the probabilistic sensitivity analysis of dabigatran treatment compared to VKA treatment in DVT over a period of 180 days from the societal perspective. Points below the diagonal line represent simulations in which dabigatran was a cost-effective alternative at a threshold of €20,000/QALY, below the x-axis, cost-saving points are shown.</p
Add to ORKG